Objective: To assess the clinical and immunologic findings in children with voltage-gated potassium channel (VGKC)-complex antibodies (Abs).
Abs can be accounted for by Abs binding to these proteins. 6 This is particularly the case in children whose titers are usually ,400 pM even when they have limbic encephalitis. 7, 8 Moreover, the VGKC-complex Ab-associated clinical phenotypes are varied and include epilepsies 9 and demyelination. 10 Because of the lack of clear relationship between VGKC-complex Abs and clinical syndromes in children, we hypothesized that the radioimmunoassay may detect binding to intracellular epitopes on the VGKC subunits themselves and be clinically irrelevant. The aim was to explore the clinical phenotypes of VGKC-complex Abs at different levels in children and to begin to dissect their targets within the VGKC-complex.
METHODS Between 2008 and 2013, 363 serum samples were sent from the Evelina London Children's Hospital (241) and Great Ormond Street Children's Hospital (122) to the Clinical Neuroimmunology service at the Oxford Radcliffe Hospital Trust requesting VGKC-complex and NMDA receptor (NMDAR) or other Ab tests. Demographic information, clinical features at presentation, discharge and follow-up, and results of laboratory, electrophysiologic, and neuroimaging testing, were compiled (Y.H.) and presented anonymously to 2 pediatric neurologists (R.S., M.L.) who were blinded to the Ab results and classified the patients using the ICD-10 into inflammatory diseases of the central and peripheral nervous system (n 5 158) and noninflammatory etiologies (n 5 205). No CSFs were available from these children for further analysis.
VGKC-complex radioimmunoprecipitation and CBAs.
VGKC-complex Abs were measured by radioimmunoassay, which involves preparation of rabbit brain digitonin-extracted VGKC complexes, labeling the extract with 125 I-dendrotoxin ( 125 I-DTX), and adding 1 and 5 mL of serum, followed by anti-human immunoglobulin G (IgG) to immunoprecipitate the complexes. The results are calculated as picomolar of 125 I-DTX precipitated 3, 11 (normal values ,100 pM). Retrospectively, all sera positive for VGKC-complex Abs were tested for Abs to NMDAR, LGI1 and contactin-2 (serum 1:20) , and to CASPR2 (serum at 1:100) using CBAs as previously described. 3 These depend on binding of IgG to human embryonic kidney (HEK) cells, transfected with complementary DNA encoding the relevant autoantigen. The binding of serum IgG to the surface of the transfected cells is visualized using a fluorescence-labeled secondary Ab. Similar CBAs were used to look for binding to ADAM22 and 23 (serum at 1:100), and for the Kv1 subunits themselves by CBA, using cells cotransfected with DNAs for Kv1.1, 1.2, and 1.6. 3, [12] [13] [14] Commercial Abs to Kv1.1, 1.2, and 1.6 (Alomone Labs, Jerusalem, Israel) were used to confirm the expression of each Kv1 subtype (see results section).
Radioimmunoassay for Abs to VGKC Kv1 subunits. This was performed to mirror the tissue extraction used for the VGKC-complex Ab assay (see above). HEK cells were seeded at 15 million/flask in 175 cm 2 flasks and grown until 40% confluent. They were transfected with a total of 60 mg of complementary DNA (e.g., 10-15 mg each of Kv1.1, 1.2, and 1.6, and the intracellular b2 subunit were cotransfected with or without PSD93 and PSD95), with 30 mL of polyethyleneimine and 25 mL of 20% glucose. After 15 hours, the medium was changed, and at 48 hours posttransfection, the flasks were washed in phosphate-buffered saline and the cells lysed in 3 mL of a 2% digitonin (Calbiochem, Billerica, MA) Trisbuffered (pH 7.12) saline with 5 mM KCl and 1:100 protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). The lysates were gently rotated for 1 hour at 4°C, spun (13,000 rpm for 5 minutes) at 4°C, and labeled with 125 I-aDTX (10 6 cpm/mL). Fifty-microliter aliquots of the extracted proteins were then used in radioimmunoassays by adding 2.5 mL of patient serum and immunoprecipitating with anti-human IgG (RSR Ltd., Cardiff, UK).
Primary mouse hippocampal and mixed neuron cultures.
To identify possible novel Abs to extracellular epitopes, primary neuronal cell cultures were established from neonatal (P1) rat brain. 3 The live neurons (days 7-9 for whole brain, days 12-15 for hippocampal neurons) were incubated with patient or control sera (diluted 1:100) at 37°C for 1 hour followed by incubation with appropriate secondary Ab before fixation/permeabilization and incubation with mouse anti-MAP2 (microtubule-associated protein 2) Ab (1:1,000; Invitrogen, Carlsbad, CA) to identify the neurons among the mixed hippocampal cultures.
Statistical analysis. Statistical analysis was performed using the commercially available software GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA). Nonparametric statistical tests (Mann-Whitney tests) were used for continuous distributions and Fisher exact tests for nominal data.
Standard protocol approvals, registrations, and patient consents. Ethical approval for further Ab testing on referred samples was from the Oxfordshire Regional Ethical Committee A (07/Q1604/28). Because the data analysis was retrospective and no additional data were collected beyond that required for standard medical care of the patient, a full ethics review under the terms of the Governance Arrangements of Research Ethics Committees in the UK was deemed not necessary by the study team.
RESULTS
Clinical diagnoses of all patients referred for testing. The clinical records for each patient sent for testing were examined and the diagnoses established. Based on the ICD-10, a primary inflammatory condition was identified in 158 patients (67 males, age range 4 months to 18 years, median 8 years) and a noninflammatory diagnosis in 205 patients (98 males, age range 2 months to 18 years, median 9 years). The stratification of the results are shown in figure 1 . Encephalopathy was the most frequent presentation (n 5 7), including one with NMDAR-Ab encephalitis. Others presented with ADS (n 5 2) or Guillain-Barré syndrome (GBS) (n 5 1). One patient presented with myositis and serum binding strongly to hippocampal neurons in a punctate pattern (data not shown), despite no evidence of CNS involvement. None of these patients' sera were positive for binding to the VGKC-complex proteins LGI1 or CASPR2. Immunotherapy was given in 10 of 11 patients with varying responses to treatments and outcomes. VGKC-complex Abs ranging from 150 to 400 pM. Seven patients had Abs in this range and presented with encephalopathy (n 5 4) and one each with acute demyelination syndrome (ADS), Lambert-Eaton myasthenic syndrome, and acute Sydenham chorea. The 4 patients who received immunotherapy made a full recovery (see table e-2).
VGKC-complex Abs >400 pM. A total of 12 patients had Ab titers .400 pM. They presented with encephalopathy (n 5 7), ADS (n 5 3), opsoclonus myoclonus syndrome (OMS) (no neuroblastoma found) (n 5 1), and GBS (n 5 1). Ten of these patients made a good recovery, in 2 cases without immunotherapy (table 2) .
Abs binding to defined components of the VGKC complex.
Only one child (table 2, case 25; VGKC-complex Ab 831 pM), a boy with a diagnosis of GBS without encephalopathy, 15 tested positive for the known VGKC-complex-associated proteins, binding to both LGI1 and CASPR2 at titers of 1:500. Autoantibodies to ADAM22 and 23 were not identified in his or any of the other 39 VGKC-complex Ab-positive sera, and there was no detectable binding to live HEK cells expressing Kv1.1, 1.2, and 1.6 either in isolation or when cotransfected with Kvb2, although all 3 monoclonal Abs bound to the live Kv1-expressing cells (data not shown).
Binding to primary rat hippocampal and mixed neuronal cultures. Only 4 patients' sera bound to live hippocampal and mixed neuronal cultures. Two of these were also positive for NMDAR Ab (one with encephalopathy and one with OMS) and one was positive for both LGI1 and CASPR2 (described above). The fourth patient was a 13-year-old girl with scleroderma who presented with acute myositis and VGKCcomplex Abs of only 112 pM (table e-2, case 3).
Binding to Kv1 subunits with or without PSD93/95. The components of the VGKC complex are illustrated in figure 2C . The lack of binding to Kv1 transfected cells could be because the Abs that immunoprecipitate VGKC complexes bind to novel complexed proteins or to intracellular determinants on the Kv1s or other components of the complex.
To find whether the Abs bind to the VGKC themselves, Kv1-expressing HEK cells, with or without the intracellular PSDs, were extracted under the same conditions used for extracting brain tissue for VGKC-complex Ab assays ( figure 2D) . The extracts were labeled with 125 I-DTX for testing the 12 sera with high titers (.400 pM) of VGKC-complex Abs. Four of the 12 (33%, cases 20, 24, 27, 28) immunoprecipitated 125 I-DTX-Kv1s; 2 patients with encephalitis bound the Kv1 subunits only, the patient with OMS bound the Kv1s when cotransfected with PSD93 and PSD95, and one patient with ADS bound to Kv1s alone or with the PSDs.
Clinical correlation with repeat samples. Further samples were available for 9 patients (6 encephalopathy, 3 ADS). VGKC-complex Abs became negative at 3-month follow-up in the 3 patients with ADS who improved (data not shown). A correlation with titer was also seen in 3 of 6 patients with encephalopathies: clinical improvement with Ab reduction in 2 ( figure 3, A and B) , with increased titer at relapse in one ( figure 3A) , and persistence of symptoms and Abs in a further patient who had very high titers of glutamic acid decarboxylase (GAD) Abs (.50,000 IU/mL; figure 3C ). However, in 3 patients with encephalopathies, there was no temporal correlation with clinical features; the VGKCcomplex Ab levels increased when asymptomatic in 2 (figure 3, D and E) and persisted despite complete recovery in one. VGKC-complex Abs were associated with a range of different phenotypes, although encephalopathies were most frequent (figure 1). (C) Theoretical representation of the VGKC complex as it sits in the membrane. For radioimmunoprecipitation assays, the complex is extracted from rabbit brain in mild detergent and labeled with 125 I-DTX, which binds strongly to VGKC Kv1 subunits. Any antibodies that bind extracellularly (red) to the proteins in the complex, specifically LGI1 and CASPR2, or any novel proteins (?), or those binding to intracellular epitopes (blue), can immunoprecipitate the VGKC complex and give a positive test result. (D) To look specifically for antibodies that bind to the VGKC themselves, the Kv1 subunits (including the b2, not shown) were expressed, with or without the PSDs, extracted, labeled with 125 I-DTX, and used in antibody assays. The antibodies that bound in this assay might be mainly against intracellular epitopes (blue). Ab 5 antibody; ADAM22 5 a disintegrin, and metalloproteinase 22; ADS 5 acquired demyelinating syndromes; CASPR2 5 contactin-associated protein 2; 125 I-DTX 5 125 I-dendrotoxin; ICD-10 5 International Classification of Diseases, Tenth Revision; LGI1 5 leucine-rich, glioma inactivated; PSD93 5 postsynaptic density protein 93; VGKC 5 voltage-gated potassium channel.
DISCUSSION
The large number of VGKC-complex Abs identified in Oxford, and the growing number in which a specific antigen has not been defined, led to concerns that the Abs might be partly binding to intracellular epitopes and would be of doubtful clinical relevance. The data presented confirm the lack of specific antigens and the probable binding of 4 of 12 high-titer sera to intracellular epitopes on the Kv1 subunits. Nevertheless, they also indicate that VGKC-complex Abs in children are more common in inflammatory conditions than in noninflammatory neurologic conditions, suggesting that they can be a nonspecific biomarker for neuronal inflammation. It is possible that these Abs occur when the nervous system is damaged, perhaps because released epitopes of the VGKC complex are able to induce autoantibodies.
Because of the retrospective nature of this study, with diagnoses established from clinical records, there was no uniformity in reporting of clinical features or time to sampling from first presentation. The children with inflammatory diseases exhibited a range of presentations ( figure 2, table 2 , tables e-1 and e-2), not all showed a clear response to immunotherapy, and Ab titers did not correlate with the clinical state in 3 of the 9 patients from whom serial samples were available ( figure 3) . Thus, it is difficult to assess the clinical relevance of the Abs in children. Abbreviations: Ab 5 antibody; GAD 5 glutamic acid decarboxylase; IVIg 5 IV immunoglobulin; MMF 5 mycophenolate mofetil; NMDAR 5 NMDA receptor; OCB 5 oligoclonal band; PLEX 5 plasma exchange; PSD 5 postsynaptic density; TPO 5 thyroid peroxidase; VGKC 5 voltage-gated potassium channel; WCC 5 white cell count; WM 5 white matter. Shown are clinical, paraclinical, and immunologic features of patients with VGKC-complex Abs in order of increasing titer. a VGKC-complex Abs at acute presentation were 277; see figure 3 for more details. The 9 patients with noninflammatory conditions and patients 1-18
with inflammatory conditions and lower VGKC-complex Ab levels are described in tables e-1 and e-2.
Moreover, although there were 39 (10.7%) positives from 363 patient samples, only 12 had Ab levels .400 pM, a useful cutoff for identifying CNS diseases. 6, 11 These high-titer VGKC-complex Abs were only present in children with inflammatory diseases as defined by ICD-10, and 7 of the 12 (58%) had encephalopathy. Two of the sera bound to hippocampal neurons, one with Abs to both the VGKC-complex-associated proteins LGI1 and CASPR2, and one with NMDAR-Ab encephalitis. None bound to the membrane VGKC-associated proteins ADAM22 or ADAM23. However, 4 additional sera immunoprecipitated Kv1 subunits extracted from HEK cells, with or without the VGKC clustering proteins PSD93 and PSD95. This suggests that even some of the high VGKC-complex Abs may be binding partly or exclusively to intracellular epitopes that are exposed in detergent extracts, although the relative sensitivities of immunoprecipitation (very high specific activity 125 I-DTX) compared to the CBAs (fluorescence detection) is not established. In this study, the overall positivity was almost double that reported in UK adult patients (5.2%; p 5 0.0005, Fisher exact test) but the number of patients with high levels (.400 pM) was not very different (2.1% vs 3.3%). 6 The positivity for LGI1 or CASPR2 Abs was very low here (1/39; 3%) compared with 17% 6 and 31% 16, 17 in adult patients, but the range of titers was similar to that reported in 12 children referred to the Mayo Clinic who were positive for VGKC-complex Ab. 18 Because only 4 of our 39 positive patients demonstrated binding to the surface of neurons (of which 3 were positive for specific antigens), it seemed likely that some of the Abs were binding to intracellular epitopes on the VGKC, Kv1s, or other complexed proteins. Four sera did bind to the isolated Kv1 subunits and 2 of these, from patients with encephalopathies, only bound to Kv1 subunits in the absence of PSDs. It is possible that the PSD proteins obscure access of some Abs to intracellular Kv1 subunit epitopes (figure 2D). PSD93 and PSD95 are part of the intracellular MAGUKs, which bind the C-terminal consensus sequence known as the PDZ-binding domain of Kv1, and are important for clustering of Kv1 at the juxtaparanodes. 1 Axoglial proteins were increased in CSF of pediatric patients with acquired demyelination syndromes, 19 which likely reflects neuronal damage; the release of these proteins could stimulate immune responses to epitopes on the VGKCs and other axonal proteins. The VGKC complex appears to be very immunogenic since inhalation of porcine brain tissue antigens led to very high serum VGKC-complex Abs in both humans and mice. 20 VGKC-complex Abs are often requested in patients with possible or suspected autoimmune forms of encephalitis, and in highly selected cohorts or isolated case reports, VGKC-complex Abs have been reported in status epilepticus, 21 fever-induced refractory epileptic encephalopathy in school-age children, 22 seizures and basal ganglia changes, 23 and focal epilepsies 9 but usually at very low levels. Here, similarly low VGKC-complex Abs (105-158 pM) were identified in 4 of the 80 patients (5%) with seizure disorders but none of these was considered immune-mediated. We did not detect the Abs in developmental and autistic regressions (n 5 27), primary psychiatric disorders (n 5 15), or functional illness (n 5 14) (table 1). Identification of low-titer Abs in primary genetic and neurometabolic disorders suggests a possible secondary inflammatory component, which might, in some cases, benefit from immunotherapy. 24 The utility of an Ab as a disease-specific biomarker requires strict clinical inclusion criteria in order to determine the applicability of the test in a clinical setting. Diagnosis of a specific disorder in Ab-positive patients with some, but not all features of a welldefined syndrome, rests on confidence in both the pathogenicity of the Ab and on the rigor of the method. As demonstrated here, identification of VGKC-complex Ab cannot be used as a positive predictive value for clinical management. Nevertheless, although there was no evidence for novel extracellular antigen(s), the association of the VGKC-complex Abs, particularly those at high titer, with inflammatory diseases, and in 20% of encephalopathies, suggests that positive VGKC-complex Abs represent a nonspecific biomarker of neuronal inflammation, without specific diagnostic relevance. 
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